The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- functional magnetic resonance imaging of the brain
研究概览
简要总结
The objective of the study is to determine whether Kuvan™ (sapropterin) improves the strength of the functional connectivity between brain regions in individuals with PKU.
详细描述
The proposed study is designed to evaluate the hypothesis that functional connectivity may represent an early marker for neurocognitive improvements related to Kuvan treatment. As a first step in the study, 20 patients with PKU who are ≥ 6 years of age will receive baseline functional connectivity magnetic resonance imaging (fcMRI) evaluations before being treated with Kuvan™. Response to Kuvan™ will be monitored for 4 weeks. At the end of 4 weeks, response to Kuvan™ will be reviewed and all 20 patients will receive follow-up fcMRI evaluations. Fifteen patients with a reduction of ≥ 20% in blood phenylalanine will continue in the study and receive a third fcMRI evaluation at the end of 6 months of treatment with Kuvan™. For comparison purposes and to control for possible practice effects in repeated testing, a matched control group of 20 healthy individuals without PKU will used. All 20 of the control subjects will receive baseline and 4-week fcMRI evaluations; fifteen will receive a 6-month evaluation.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willing and able to provide informed consent or assent.
- •Willing and able to comply with study procedures.
- •Greater than or equal to 6 years of age.
- •For phenylketonuria, intention of physician to prescribe sapropterin.
- •For phenylketonuria, phenylalanine level greater than or equal to 300μmol/L.
- •For phenylketonuria, negative pregnancy test if of childbearing potential.
- •For phenylketonuria, willing to use contraception if sexually active.
排除标准
- •Pregnant, breastfeeding, or planning to become pregnant during study.
- •Use of investigational product less than 30 days prior to or during study.
- •Concurrent condition that could interfere with participation or safety.
- •Any condition creating high risk of poor compliance with study.
- •Perceived to be unreliable or unavailable for study.
- •Use of L-Dopa, methotrexate, or other drugs that inhibit folate metabolism.
- •For phenylketonuria, known hypersensitivity to sapropterin or excipients.
研究组 & 干预措施
Sapropterin
Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
干预措施: Sapropterin (Drug)
结局指标
主要结局
functional magnetic resonance imaging of the brain
时间窗: baseline, 4 week, & 6 month follow-up
次要结局
未报告次要终点
研究者
Shawn Christ
Prof Assoc, Psychological Sciences
University of Missouri-Columbia